The ProAct database was generated a decade ago, which may explain some hesitation for the market embracing the comparison - drawing the seemingly natural conclusion that there has been improvements to the standard of care since then.
But I understand that the Healy Platform placebo group actually has a slightly shorter life expectancy than the ProAct Database demonstrates. Meaning our results measured against Healy Placebo would be even better!
So no doubt the sooner we can commence Healy the better!
Ann: Positive Interim Study Results from OLE Study in ALS, page-44
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NUZ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $93.42M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 19.5¢ | 19.0¢ | $31.22K | 164.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 362647 | 18.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 66191 | 2 |
View Market Depth
| Last trade - 14.37pm 05/11/2024 (20 minute delay) ? |
| NUZ (ASX) Chart |